Peter Zhang, Ph.D. has over 25 years of experience in the Pharmaceutical Industry with a diverse experience in Drug Development including preclinical, Phase I/II/III/IV and also life cycle management (LCM). He has also supported more than 15 NDAs/sNDAs/MAAs/NDS/PMDA. and several INDs across various therapeutic areas including CNS (Alzheimer’s disease, MDD, Schizophrenia, Bipolar, ADHD), Cardiovascular (BP, ACS, Intermittent Claudication), Respiratory disease (Asthma, COPD, RDS), Gastrointestinal Disease (Ulcerative Colitis, IBD, Crohn’s Disease), Anti-Infection (UTI, LRTI, MDR-TB), Oncology (Advance colorectal cancer, MDS, AML, Cancer Pain, and CML), and Ophthalmology (Dry eye, Dry AMD). The hallmark of his career is his successful leadership in biostatistics, programming, quantitative analytics, statistical reporting, global drug development, and global medical affairs/HEOR, and CMC & QC at several pharmaceutical companies in the United States such as Procter & Gamble Pharmaceuticals, Novartis Pharmaceuticals, Forest Laboratories (now Allergan), and Otsuka Pharmaceutical Development and Commercialization, Inc. Peter is currently Head of Biostatistics Department at Otsuka Pharmaceuticals (US) that focusses on collecting, integrating, analyzing, interpreting and providing insight from the many data sources that exist across various functions.
Peter has published over 110 abstracts and manuscripts in various international statistical and medical Journals. He has also written several book chapters. His research interest areas are the nonparametric Bayesian method, meta-analysis/network meta-analysis, missing data, enrichment clinical trial design, and SPCD/re-randomization design. He graduated with a Ph.D. in Statistics from Purdue University, an M.S. in Computing Statistics from Chinese Academy of Sciences, and a B.S. in Mathematics from Peking University.